BioFire
BioMérieux Gets Health Canada Approval for Updated BioFire Blood Culture ID Panel
The panel includes additional pathogen targets and resistance genes, as well as revised targets compared to the original BCID panel.
BioMérieux Joint Infection Panel Gets FDA De Novo Authorization
The 39-target panel runs on FilmArray systems and tests for 31 pathogens implicated in most acute joint infections as well as eight antimicrobial resistance genes.
BioMérieux Reports 8 Percent Revenue Growth in Q4
The firm is expecting an overall sales decline in 2022 due to decreased demand for COVID-related products as the disease becomes endemic.
Newly merged with a firm founded by BioFire Diagnostics alums, Co-Diagnostics plans to develop small panels for the system with up to six targets.
Streck Gets FDA Clearance for BioFire Sepsis Panel Control Material
The process control contains 43 intact, inactivated bacteria, yeasts, and antimicrobial resistance targets to validate the syndromic PCR sepsis panel.